Advanced Esophageal Squamous Carcinoma
Conditions
Brief summary
Irinotecan, as one new agent used in advanced esophageal carcinoma, has been shown to be effective and safe in western studies. Different with westerns, squamous carcinoma is the main pathological type in china patients. The investigators then initiated a prospective phase II clinical trial with irinotecan/cisplatin as the 1st line treatment in advanced esophageal carcinoma to observe the efficacy and safety of the combination.
Interventions
DRUGirinotecan/cisplatin
irinotecan 130mg/m2 d1 cisplatin 30mg/m2, d1,d2 every 3 weeks
Sponsors
Peking University
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Having signed informed consent * Age 18 to 70 years old * Histologically confirmed esophageal squamous carcinoma, no prior palliative chemotherapy; recurrence from last adjuvant chemotherapy or adjuvant radiotherapy should be longer than 6 months; no prior treatment of irinotecan as adjuvant chemotherapy, total dose of cisplatin is less than 300mg/m2 if used in adjuvant chemotherapy * Unresectable recurrent or metastatic disease * Measurable disease according to the RECIST criteria(diameter of the lesion should be more than 10mm by spiral CT or MRI, more than 20mm by common CT, the date of image should be less than 15 days before enrollment) * Karnofsky performance status ≥70 * Life expectancy of ≥3 month * No prior radiotherapy except radiotherapy at non-target lesion of the study more than 4 weeks * ALT and AST\<2.5 times ULN (≤5 times ULN in patients with liver metastases)(within 7 days before enrollment) * Serum AKP \< 2.5 times ULN (within 7 days before enrollment) * Serum creatinine \<1.0 times ULN (within 7 days before enrollment) * Bilirubin level \< 1.0 times ULN (within 7 days before enrollment) * WBC\>4,000/mm3, absolute neutrophil count ≥2000/mm3, platelet\>100,000/mm3, Hb\>9g/dl(within 7 days before enrollment) * No sever complication, such as active gastrointestinal bleeding, perforation, jaundice, obstruction, non-cancerous fever\>38℃； * Good compliance
Exclusion criteria
* previous treatment of palliative chemotherapy or recurrence less than 6 months from time of last adjuvant chemo-/radiotherapy * Known hypersensitivity to irinotecan * Only with Brain or bone metastasis * Tumor with length≥10cm, liver metastasis covers more than 50% of liver,or lung metastasis covers more than 25% of lung * No measurable lesions, eg. pleural fluid and ascites * Surgery (excluding diagnostic biopsy) within 4 weeks prior to study entry * Heart failure or other sever organ dysfunction, eg. coronary artery disease, myocardial infarction within the last 6 months or * Pregnancy or lactation period * Other previous malignancy within 5 year, except non-melanoma skin cancer * Chronic diarrhea * Mentally abnormal or disable cognition,including CNS metastasis
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| overall survival | 2 year |
Secondary
| Measure | Time frame |
|---|---|
| PFS | 1year |
| response rate | 1.5 months |
| adverse events | 2 year |
| polymorphism of UGT1A | 2 year |
Countries
China
Contacts
Primary Contactzhang xiaodong, MD
Backup Contactzhang xiaotian, MD
Outcome results
None listed